OnKure Therapeutics Management
Management criteria checks 1/4
OnKure Therapeutics' CEO is Nick Saccomano, appointed in Sep 2023, has a tenure of 1.58 years. total yearly compensation is $9.52M, comprised of 4.9% salary and 95.1% bonuses, including company stock and options. directly owns 0.027% of the company’s shares, worth $10.90K. The average tenure of the management team and the board of directors is 1.6 years and 4.1 years respectively.
Key information
Nick Saccomano
Chief executive officer
US$9.5m
Total compensation
| CEO salary percentage | 4.9% |
| CEO tenure | 1.6yrs |
| CEO ownership | 0.03% |
| Management average tenure | 1.6yrs |
| Board average tenure | 4.1yrs |
Recent management updates
No updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2024 | US$10m | US$462k | -US$53m |
| Sep 30 2024 | n/a | n/a | -US$45m |
| Jun 30 2024 | n/a | n/a | -US$42m |
| Mar 31 2024 | n/a | n/a | -US$36m |
| Dec 31 2023 | US$346k | US$68k | -US$35m |
Compensation vs Market: Nick's total compensation ($USD9.52M) is above average for companies of similar size in the US market ($USD662.66K).
Compensation vs Earnings: Nick's compensation has increased whilst the company is unprofitable.
CEO
Nick Saccomano (65 yo)
1.6yrs
Tenure
US$9,515,165
Compensation
Dr. Nicholas A. Saccomano, Ph D., also known as Nick, serves as President & Chief Executive Officer at OnKure Therapeutics, Inc. from September 2023 and is its Director since January 2022. He serves as Dir...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 1.6yrs | US$9.52m | 0.027% $ 10.9k | |
| Chief Financial Officer | 3.3yrs | US$2.68m | 0.030% $ 11.9k | |
| Chief Medical Officer | 1.2yrs | US$2.88m | 0% $ 0 | |
| Chief Scientific Officer | less than a year | no data | 0% $ 0 | |
| General Counsel & Secretary | less than a year | no data | no data | |
| Senior Vice President of Computational Drug Discovery | 3.8yrs | no data | 0.87% $ 347.8k | |
| Chief Development Officer | 3.7yrs | no data | no data | |
| Senior Vice President of DMPK & Clinical Pharmacology | 2.8yrs | no data | no data | |
| Senior Vice President of Discovery Chemistry | no data | no data | no data | |
| Senior VP of Clinical Operations | less than a year | no data | no data |
1.6yrs
Average Tenure
53yo
Average Age
Experienced Management: OKUR's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 4.3yrs | US$9.52m | 0.027% $ 10.9k | |
| Director | less than a year | US$333.41k | 0.69% $ 274.7k | |
| Independent Director | 4.1yrs | US$291.30k | 0% $ 0 | |
| Independent Director | less than a year | US$296.58k | 0.019% $ 7.6k | |
| Independent Director | 4.1yrs | US$262.31k | 0.026% $ 10.3k | |
| Independent Chairman | 4.1yrs | US$268.89k | 0% $ 0 | |
| Independent Director | less than a year | US$258.29k | 0% $ 0 |
4.1yrs
Average Tenure
64yo
Average Age
Experienced Board: OKUR's board of directors are considered experienced (4.1 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/11 16:46 |
| End of Day Share Price | 2025/04/11 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
OnKure Therapeutics, Inc. is covered by 4 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Robert Burns | H.C. Wainwright & Co. |
| Soumit Roy | JonesTrading Institutional Services, LLC |
| Andrew Berens | Leerink Partners LLC |